These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 24263002)

  • 21. Inhibition of Tissue Factor Pathway Inhibitor (TFPI) as a Treatment for Haemophilia: Rationale with Focus on Concizumab.
    Chowdary P
    Drugs; 2018 Jun; 78(9):881-890. PubMed ID: 29845491
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Blocking of tissue factor pathway inhibitor (TFPI) shortens the bleeding time in rabbits with antibody induced haemophilia A.
    Erhardtsen E; Ezban M; Madsen MT; Diness V; Glazer S; Hedner U; Nordfang O
    Blood Coagul Fibrinolysis; 1995 Jul; 6(5):388-94. PubMed ID: 8589204
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sensitivity and Robustness of Spatially Dependent Thrombin Generation and Fibrin Clot Propagation.
    Kuprash AD; Shibeko AM; Vijay R; Nair SC; Srivastava A; Ataullakhanov FI; Panteleev MA; Balandina AN
    Biophys J; 2018 Dec; 115(12):2461-2473. PubMed ID: 30514632
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The relevance of factor VIII (FVIII) pharmacokinetics to TDM and hemophilia a treatment: is B domain-deleted FVIII equivalent to full-length FVIII?
    Johnston A
    Ther Drug Monit; 2012 Feb; 34(1):110-7. PubMed ID: 22249347
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Turoctocog alfa for the treatment of hemophilia A.
    Haddley K
    Drugs Today (Barc); 2014 Feb; 50(2):121-31. PubMed ID: 24619589
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tranexamic acid combined with recombinant factor VIII increases clot resistance to accelerated fibrinolysis in severe hemophilia A.
    Hvas AM; Sørensen HT; Norengaard L; Christiansen K; Ingerslev J; Sørensen B
    J Thromb Haemost; 2007 Dec; 5(12):2408-14. PubMed ID: 18034766
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Coagulation potential of immobilised factor VIII in flow-dependent fibrin generation on platelet surfaces.
    Doi M; Sugimoto M; Matsui H; Matsunari Y; Shima M
    Thromb Haemost; 2013 Aug; 110(2):316-22. PubMed ID: 23636463
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Successful immune tolerance induction with high-dose coagulation factor VIII and intravenous immunoglobulins in a patient with congenital hemophilia and high-titer inhibitor of coagulation factor VIII despite unfavorable prognosis for the therapy.
    Kubisz P; Plamenová I; Hollý P; Stasko J
    Med Sci Monit; 2009 Jun; 15(6):CS105-11. PubMed ID: 19488019
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluation of a novel flow chamber system to assess clot formation in factor VIII-deficient mouse and anti-factor IXa-treated human blood.
    Ogawa S; Szlam F; Dunn AL; Bolliger D; Ohnishi T; Hosokawa K; Tanaka KA
    Haemophilia; 2012 Nov; 18(6):926-32. PubMed ID: 22642581
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Aptamer BAX 499 mediates inhibition of tissue factor pathway inhibitor via interaction with multiple domains of the protein.
    Waters EK; Genga RM; Thomson HA; Kurz JC; Schaub RG; Scheiflinger F; McGinness KE
    J Thromb Haemost; 2013 Jun; 11(6):1137-45. PubMed ID: 23528042
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clot waveform analysis using CS-2000i™ distinguishes between very low and absent levels of factor VIII activity in patients with severe haemophilia A.
    Matsumoto T; Nogami K; Tabuchi Y; Yada K; Ogiwara K; Kurono H; Arai N; Shima M
    Haemophilia; 2017 Sep; 23(5):e427-e435. PubMed ID: 28750470
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Factor XI enhances fibrin generation and inhibits fibrinolysis in a coagulation model initiated by surface-coated tissue factor.
    von dem Borne PA; Cox LM; Bouma BN
    Blood Coagul Fibrinolysis; 2006 Jun; 17(4):251-7. PubMed ID: 16651866
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The impact of tissue factor pathway inhibitor on coagulation kinetics determined by thrombelastography.
    Audu P; Nielsen VG; Armstead V; Powell G; Kim J; Kim L; Mehta M
    Anesth Analg; 2006 Oct; 103(4):841-5. PubMed ID: 17000790
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Intranasal DDAVP induced increases in plasma von Willebrand factor alter the pharmacokinetics of high-purity factor VIII concentrates in severe haemophilia A patients.
    Deitcher SR; Tuller J; Johnson JA
    Haemophilia; 1999 Mar; 5(2):88-95. PubMed ID: 10215955
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Diagnostic testing for mild hemophilia a in patients with discrepant one-stage, two-stage, and chromogenic factor VIII:C assays.
    Duncan EM; Rodgers SE; McRae SJ
    Semin Thromb Hemost; 2013 Apr; 39(3):272-82. PubMed ID: 23460037
    [TBL] [Abstract][Full Text] [Related]  

  • 36. In vitro reactivity of factor VIII inhibitors with von Willebrand factor in different commercial factor VIII concentrates.
    Tagariello G; Zanotto D; Radossi P; Sartori R; Belvini D; Salviato R
    Am J Hematol; 2007 Jun; 82(6):460-2. PubMed ID: 17211843
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Thrombomodulin-modified thrombin generation after in vivo recombinant factor VIII treatment in severe hemophilia A.
    Dielis AW; Balliël WM; van Oerle R; Hermens WT; Spronk HM; Ten Cate H; Hamulyák K
    Haematologica; 2008 Sep; 93(9):1351-7. PubMed ID: 18641016
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Performance of recalibrated ReFacto laboratory standard in the measurement of FVIII plasma concentration via the chromogenic and one-stage assays after infusion of recalibrated ReFacto (B-domain deleted recombinant factor VIII).
    Santoro C; Iorio A; Ferrante F; Pallotta A; Pignoloni P; Biondo F; Agnelli G; Mazzucconi MG
    Haemophilia; 2009 May; 15(3):779-87. PubMed ID: 19298379
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Factor VIII efficient and specific non-covalent binding to PEGylated liposomes enables prolongation of its circulation time and haemostatic efficacy.
    Baru M; Carmel-Goren L; Barenholz Y; Dayan I; Ostropolets S; Slepoy I; Gvirtzer N; Fukson V; Spira J
    Thromb Haemost; 2005 Jun; 93(6):1061-8. PubMed ID: 15968389
    [TBL] [Abstract][Full Text] [Related]  

  • 40. New protocol for immune tolerance induction in acquired hemophilia.
    Nemes L; Pitlik E
    Haematologica; 2000 Oct; 85(10 Suppl):64-8. PubMed ID: 11187874
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.